𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hydroxylation polymorphism of debrisoquine hydroxylase (CYP2D6) in patients with schizophrenia in Norway and Denmark

✍ Scribed by Alv A. Dahl; Anette Løwert; Sigurd Asserson; Lennart Bjarking; Johan Berglund; Flemming Kristensen; Dag Norum; Sverre Tønseth; Lotte Bayer; Eli Mæhlum

Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
77 KB
Volume
13
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

Ulla Vilsgaard

📜 SIMILAR VOLUMES

Rarity of debrisoquine hydroxylase gene
Rarity of debrisoquine hydroxylase gene polymorphism in chinese patients with Parkinson's disease
✍ Dr. Chi P. Pang; Jun Zhang; Jean Woo; Daniel Chan; Lap K. Law; Shirley F. Tong; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 415 KB

## Abstract Impaired debrisoquine metabolism resulting from defects in the cytochrome P450 __CYP2D6__‐debrisoquine hydroxylase gene has been shown to be associated with the development of Parkinson's disease(PD). We studied two polymorphisms in this gene in 207 Chinese PD patients and 227 control s

Effects of the CYP2D6*10 alleles and co-
Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia
✍ Tatsuhiko Yagihashi; Masafumi Mizuno; Bun Chino; Yuji Sato; Kei Sakuma; Toru Tak 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB

## Abstract ## Objective Risperidone is converted to 9‐hydroxyrisperidone by CYP2D6. Two parameters were used to examine the influences of CYP2D6 polymorphism and of co‐medication on risperidone metabolism: the risperidone:9‐hydroxyrisperidone concentration ratio (R:9‐OHR ratio) and the sum of the

Genetic polymorphisms of CYP2D6*10 and C
Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen
✍ Matthew Goetz; Vera Suman 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 1 views

The study by Okishiro et al 1 concludes that the cytochrome P450 (CYP) genotype CYP2D6\*10/\*10 is unlikely to have a clinically significant impact on prognosis in women with breast cancer who receive adjuvant tamoxifen. However, several aspects of the study by Okishiro et al call their conclusions